Physician profile
James L Dunn
NPI 1144310095
$1,987.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $655 · 2021: $832 · 2022: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $454.92 | 2019-2022 | |
| Abbvie INC. | $414.37 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $279.04 | 2019-2021 | |
| Lilly USA, LLC | $250.95 | 2019-2021 | |
| Allergan, INC. | $164.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $106.41 | 2019-2022 | |
| Astellas Pharma US INC | $78.36 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.78 | 2019-2022 | |
| Pfizer INC. | $36.14 | 2020-2021 | |
| Eisai INC. | $29.37 | 2022 | |
| Biogen, INC. | $28.48 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.75 | 2021 | |
| Medtronic, INC. | $24.41 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.